Combined agents for treatment of glaucoma

Details Combined agents for treatment of glaucoma Combined agents for treatment of glaucoma

2007-12-11

2007-12-11

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S913000, C514S922000

Reexamination Certificate

active

10146747

ABSTRACT:
A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, a prostaglandin and a carbonic anhydrase inhibitor; and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.

REFERENCES:
patent: 5175161 (1992-12-01), Yokoyama et al.
patent: 5182264 (1993-01-01), Watkins
patent: 5250521 (1993-10-01), Allen et al.
patent: 5273976 (1993-12-01), Yokoyama et al.
patent: 5925664 (1999-07-01), Yokoyama et al.
patent: 6777436 (2004-08-01), Yokoyama et al.
patent: 2 247 208 (1997-09-01), None
patent: 2 293 325 (1998-11-01), None
patent: 1075634 (1993-09-01), None
patent: 42299 (1984-09-01), None
patent: 189 690 (1986-08-01), None
patent: 0 296 879 (1988-12-01), None
patent: 0 375 299 (1990-06-01), None
patent: 490587 (1992-06-01), None
patent: 0 628 313 (1994-12-01), None
patent: 631780 (1995-01-01), None
patent: 639 563 (1995-02-01), None
patent: 795 326 (1997-09-01), None
patent: 1253710 (1971-11-01), None
patent: 1398455 (1975-06-01), None
patent: 64-026518 (1989-01-01), None
patent: 64-26518 (1989-01-01), None
patent: WO 90/02533 (1990-03-01), None
patent: WO 90/02553 (1990-03-01), None
patent: 91/15206 (1991-10-01), None
patent: WO 92/20342 (1992-11-01), None
patent: 93/16701 (1993-09-01), None
patent: 95/21609 (1995-08-01), None
patent: 95/24902 (1995-09-01), None
patent: WO 97/37688 (1997-10-01), None
patent: 98/41208 (1998-09-01), None
H.J. Kaiser, T. Graf, G. Krejci, G.A. Mathis, A Jauch and J. Flammer, “A New Angiotensin-II-Receptor Blocker, CGP 48933 : Local Tolerance and Effect on Intraocular Pressure. A Pilot Study”,European Journal of Ophthalmology, 1, 1997, 35-39.
Z. S. Popova, T. N. Terkhina, “Our Experience of Applying Prostaglandin F2 Alpha Analogue—Latanoprost (Xalatan) for Treating Glaucoma”,Kremlevskaya Medicinia, Klinichesky Vestnik, No. 4, (Oct.-Dec. 2000), pp. 78-79.
Z.S. Popova, T.N. Terekhina, “Trial of using latanoprost (xalathane), the analogue of prostaglandin F2-alpha, in glaucoma therapy,”Kreml. Med.: Clin Vestn., 2000, No. 4, pp. 78-79.
Hejkal TW et al.,Semin Ophthalmol., 1999, 14(3), pp. 114-123.
Camras CB et al.,Am. J. Ophthalmol., 1998, 126(3) , pp. 390-391.
Camras CB, Alm A, Watson P, Stjernschantz J., Group USLS. Fechtner RD, “Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after one year of treatment in 198 patients,”Ophthalmology, 1996, 103(11), 1916-1924.

Affiliated with

Also associated with

Rating

Combined agents for treatment of glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined agents for treatment of glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined agents for treatment of glaucoma will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3879486